Eliminating tuberculosis is possible. Yet, this preventable and largely treatable infectious disease takes the lives of 1.5 million people every year. The COVID-19 pandemic has jeopardized years of painstaking progress on eliminating the disease. The time for paradigm shift and a renewed focus on TB is now. In the run-up to the 2023 U.N. high level meeting on TB, join Devex and Stop TB Partnership in the #TalkingTB series.
Throughout this series, we’ll explore how to get efforts to end TB back on track — from hearing about the realities of living with the disease, to how technology could be leveraged to help, and what lessons can be learned from other diseases to tackle tuberculosis.
In two weeks, the board of the Global Fund to Fight AIDS, Tuberculosis and Malaria will be meeting to decide how much total grant funding will be made available to countries in the next three years, without additional pledges from big donors such as the U.K.
The Global Fund has asked donors to increase their contributions by 30% over 2019 levels due to the devastating impact of COVID-19 on health services. Advocates around the world are looking to Canada to set this precedent.
Short-course rifapentine-based TB regimens help patients complete their preventive treatment, compared to taking multiple pills daily for six months. Health organizations hope the reduced pricing will lead more countries to roll out the shorter regimen.
Devex is the media platform for the global development community. A social enterprise, we connect and inform over one million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people.
The Stop TB Partnership brings together expertise from a broad spectrum of country, regional, and global partners in our shared mission to revolutionize the TB space and end TB by 2030.